2 completed, 1 unknown. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Unknown 1 |
Follow AADvac1: new trials by email Literature Review of AADvac1 trials Research Report on AADvac1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia AADvac1 40 µg, AADvac1 160 µg - Primary Progressive Nonfluent Aphasia | Phase 1 | Unknown | Axon Neuroscience SE | 33 | 2017-07-31 | 2019-11-14 |
| 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease AADvac1 - Alzheimer's Disease | Phase 1 | Completed | Axon Neuroscience SE | 25 | 2014-01-01 | 2017-03-17 |
| Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease AADvac1, Placebo - Alzheimer Disease | Phase 1 | Completed | Axon Neuroscience SE | 30 | 2013-05-01 | 2015-10-12 |
Alzheimer Disease (2) · Pick Disease of the Brain (2) · Aphasia, Primary Progressive (1) · Dementia (1) · Frontotemporal Dementia (1) · Primary Progressive Nonfluent Aphasia (1) · Tauopathies (1)
Austria (2) · Germany (1)
Reinhold Schmidt, Professor (2) · Markus Otto, Prof (1)
PMID 27955995, PMID 30355322, PMID 25478017
2017 (1)